XML 37 R25.htm IDEA: XBRL DOCUMENT v3.25.3
Fair Value Disclosures (Tables)
9 Months Ended
Sep. 30, 2025
Fair Value Disclosures [Abstract]  
Schedule of Assets Measured on Recurring Basis
The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024.
Fair Value Measurements at Reporting Date Using
Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs
As of September 30, 2025Total(Level 1)(Level 2)(Level 3)
Cash Equivalents:
Money Market Funds$3,633,176 $3,633,176 $— $— 
Total Cash Equivalents Measured at Fair Value$3,633,176 $3,633,176 $— $— 
Short-term Investments:
Government Agency Securities$10,209,139 $— $10,209,139 $— 
Corporate Debt Securities3,657,407 — 3,657,407 — 
Total Short-term Investments Measured at Fair Value$13,866,546 $— $13,866,546 $— 
Total Assets Measured at Fair Value$17,499,722 $3,633,176 $13,866,546 $— 

Fair Value Measurements at Reporting Date Using
Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs
As of December 31, 2024Total(Level 1)(Level 2)(Level 3)
Cash Equivalents:
Money Market Funds$562,604 $562,604 $— $— 
US Treasury Securities691,917 — 691,917 — 
Total Cash Equivalents Measured at Fair Value$1,254,521 $562,604 $691,917 $— 
Short-term Investments:
US Treasury Securities$92,314 $— $92,314 $— 
Government Agency Securities18,540,550 — 18,540,550 — 
Corporate Debt Securities4,062,673 — 4,062,673 — 
Asset Backed Securities304,223 — 304,223 — 
Total Short-term Investments Measured at Fair Value$22,999,760 $— $22,999,760 $— 
Total Assets Measured at Fair Value$24,254,281 $562,604 $23,691,677 $— 
Schedule of Liabilities Measured on Recurring Basis The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:
September 30, 2025December 31, 2024
Contingent Consideration:
Non-current$2,883,423 $4,191,490 
Total Contingent Consideration$2,883,423 $4,191,490 
Schedule of Unobservable Level 3 Inputs After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:
Valuation TechniqueUnobservable InputsSeptember 30, 2025December 31, 2024
Discounted cash flowPayment discount rate13.9 %15.1 %
BayonPayment period2027 - 20302027 - 2029
PanoptesPayment period2029 - 20312027 - 2028
BayonProbability of success for payment
25% - 45%
48% - 77%
PanoptesProbability of success for payment
30% - 33%
30% - 33%
The Company engaged a third-party valuation firm to assist management to perform its quantitative assessment of in-process R&D as of August 31, 2025, which includes the following unobservable Level 3 inputs:
Valuation TechniqueUnobservable InputsDiscount Rate
KIO-104Multi-Period Excess Earnings MethodProbability of success for next development phase
17% to 36%
35.5%
KIO-301Multi-Period Excess Earnings MethodProbability of success for next development phase
25% to 45%
35.5%